

COST Action TD0901
HypOxiaNet

Workshop: PHD inhibiting drugs

DAVOS OXYGEN 2011 Conference, 11.01.2011

Program

12:30-14:45

(WG3, Co-chairs **Philip Smith and Chris Schofield**)

This is a discussion forum (open to all participants)

1. Introduction to 2OG Oxygenase Inhibitors
Chris Schofield, University of Oxford, 15 mins
2. Exploring Therapeutic Applications for Cytoprotective HIF-PHI
Gail Walkinshaw, Fibrogen, 40 mins
3. Zebrafish as an *in vivo* screening tool for modulators of HIF signalling
Feek van Eeden, University of Sheffield, 20 mins
4. Title to be announced,
Terrance Barrett, Johnson and Johnson, 30 mins
5. Round Table discussion on how best to forge links between academic and the pharmaceutical industry with respect to developing clinically useful HIF hydroxylase inhibitors, 30 mins (Chair Philip Smith, Novartis, UK)

Further details will be announced during the meeting.

Conclusions by Chris Schofield:

Many thanks for your contributions to the the Workshop at the Davos Oxygen 2011 conference on HIF hydroxylase inhibitors - even if you were not able to attend / contribute your support / interest was much appreciated.

In particular we would like to thank the pharmaceutical contributors. I think there was strong feeling that we would like to maintain strong links between the academic and pharmaceutical groups via either workshops or sessions at future hypoxia meetings in the US and Europe (next at Keystones). As we discussed presentations don't always have to be 'ground breaking' or from senior researchers - any contribution from the pharmaceutical side is very much appreciated. In return I hope our academic groups can deliver some interesting basic science that will help in drug development. We'd genuinely like to see something useful come out of the hypoxia field in terms of a product.

I hope to see you all at future meetings - someone will be in touch regarding Keystone / HypoxiaNet.

All the best,

Chris Schofield.